LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 3.36 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Proteome Sciences Stock (LON:PRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Proteome Sciences alerts:Sign Up Key Stats Today's Range 3.02▼ 3.3650-Day Range 2.50▼ 3.9952-Week Range 2.22▼ 5.40Volume13,904 shsAverage Volume216,544 shsMarket Capitalization£9.92 millionP/E RatioN/ADividend Yield6.17%Price TargetN/AConsensus RatingN/A Company OverviewProteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.Read More… Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRM Stock News HeadlinesProteome Sciences shares rise as chair hails rebound in businessMay 16, 2025 | lse.co.ukProteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)April 12, 2025 | finance.yahoo.comBanks aren’t ready for this altcoin—are you?Crypto Market In Rare Form For Rapid Wealth Building When you've been in crypto as long as I have, you learn to recognize the signs and right now, I'm seeing something that's keeping me up at night.June 14, 2025 | Crypto 101 Media (Ad)Proteome Sciences Secures £1 Million Loan to Boost Capacity Amid Market GrowthDecember 23, 2024 | tipranks.comProteomics and AI unite for a new era in medicine and health careDecember 12, 2024 | msn.comNanoparticle approach enhances detection of low-abundance proteins in blood plasmaNovember 9, 2024 | msn.comProteome Sciences plc (PRM.L)November 6, 2024 | finance.yahoo.comBruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and MetaproteomicsOctober 21, 2024 | tmcnet.comSee More Headlines PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 3.40 at the start of the year. Since then, PRM shares have decreased by 1.2% and is now trading at GBX 3.36. View the best growth stocks for 2025 here. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) released its earnings results on Thursday, April, 10th. The company reported ($1.15) earnings per share for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative trailing twelve-month return on equity of 0.01%. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings4/10/2025Today6/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryChemicals Current SymbolLON:PRM CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees240Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.08 million Net Margins-0.04% Pretax MarginN/A Return on Equity-0.01% Return on Assets-19.25% Debt Debt-to-Equity Ratio-258.66 Current Ratio0.20 Quick Ratio0.37 Sales & Book Value Annual Sales£10.88 billion Price / Sales0.00 Cash FlowGBX 0.90 per share Price / Cash Flow3.73 Book ValueGBX (1.78) per share Price / Book-1.88Miscellaneous Outstanding Shares295,167,274Free FloatN/AMarket Cap£9.92 million OptionableNot Optionable Beta0.07 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (LON:PRM) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.